全直肠系膜切除术治疗直肠癌--附168例报告

目的　探讨全直肠系膜切除术在预防直肠癌术后局部复发中的作用 ,以及同该操作相关的一些并发症。方法　回顾性分析 16 8例直肠癌的临床资料。结果　全组无手术死亡 ,术后随访1～ 36月 ,局部复发 6例 (3.6 % ) ,术后吻合口漏 13例 (10 .7% ) ,多数保肛患者出现便频、便急等症状。结论　全直肠系膜切除术能有效降低直肠癌术后局部复发率 ,提高保肛率 ,但存在吻合口漏 ,控便功能等问题需进一步解决。     

回盲部恶性肿瘤的诊治

目的：分析回盲部恶性肿瘤的诊断和治疗过程，总结经验．以期提高早期确诊率和患者生存率。方法：回顾性分析近5年53例住院治疗的回盲部恶性肿瘤患者的临床资料。结果：53例患者中腺癌、黏液腺癌50例，恶性淋巴瘤3例。首次确诊率为75．5％。误诊或延迟诊断的疾病主要为阑尾炎、阑尾脓肿，胆囊炎、胆石症、下消化道出血、贫血待查等。结论：60岁以上的老年患者为回盲部恶性肿瘤的主要人群，肿瘤类型主要为腺癌。尽管首发症状缺乏特异性，但提高警觉性，详细询问病史，通过大便隐血试验、钡灌肠或气钡双重造影、纤维结肠镜检查仍能有效的提高首次确诊率，积极手术冶疗，可显著改善患者的预后。     

305例尿石成份分析及预防对策

目的研究一种快速、简便的方法对泌尿系结石进行分析,并探讨其防治方法。方法用化学常量法对305例患者的尿石标本进行化学成份测定,并结合临床资料进行分析。结果发现结石发病男性多于女性(比例为3.2∶1),20~50岁多发,上尿路结石多于下尿路结石(5.4∶1)。结石中草酸钙检出率达82%,尿酸盐55.2%,磷酸钙48.6%,磷酸镁铵与碳酸磷灰石则多见于泌尿系感染病例,胱氨酸结石少见。结论化学常量法分析泌尿系结石简便、快捷、准确。结石成份分析对于了解结石成因、预防结石复发具有一定的意义。     

包皮过长和包茎组织中触觉小体观察

目的观察包茎和包皮过长组织中触觉小体差异情况。方法收集21~25岁年龄组包皮标本44例,按包皮解剖形态分为:①包茎组21例;②包皮过长组23例。用免疫组化方法对两组包皮标本中的触觉小体进行染色,在放大100倍的视野下观察和统计两组包皮标本中触觉小体总数以及视野的总数,并用卡方检验对两组间的差异进行统计学分析。结果两组标本中,分别有8个(8/21包茎组)和10个(10/23包皮过长组)标本中未发现触觉小体,其差异无显著性(P=0.717)。包茎组和包皮过长组中触觉小体的密度分别为33.1%和21.1%,差异具显著性(P=0.022)。结论包茎中触觉小体密度较包皮过长明显升高可能是一种生理性代偿机制,而两种包皮组织中触觉小体的消失可能遵循同一规律。     

Nucleotide Sequence of the ADH23 Gene Encoding the Human Alcohol Dehydrogenase β3 Subunit

All nine exons of the ADH2(3) allele, which encodes the human alcohol dehydrogenase beta 3 subunit, have been cloned and sequenced. Comparison of this sequence to the ADH2(1) nucleotide sequence revealed only a single difference that results in an amino acid change, thus proving that the significant kinetic differences between these two isozymes is due to the Cys for Arg substitution at position 369. There are also two silent polymorphisms, and two changes in noncoding regions.     

随机系统的最小熵控制

本文放弃传统的MSE准则,从信息论观点出发,发展了随机系统的一种最小熵(ME)控制方法,并从ME控制的等价性、控制限度、存在性、唯一性及必要条件等方面,研究了ME控制的合理性和实用性。ME方法是一种全局分析法,它不仅包含了MSE和MAP准则,且由于全文在整个推导中并未假定高斯性、线性和非时变等,因而原则上适用于诸如非高斯、非线性、时变等传统方法难以处理的复杂系统;不仅适用于工程系统,将其推广到决策、社会、经济等领域会更为自然和切合实际。     

Development and optimization of an indirect enzyme-linked immunosorbent assay for the determination of Hexoestrol

An indirect enzyme-linked immunosorbent assay (ELISA) for the detection of hexoestrol (HES) was developed, optimized and validated for the analysis of HES in pork. Many parameters, such as the volume ratio of solution A and solution B, colour developing time, pH value, incubation time, the volume ratio of the standard solution and diluted antiserum, blocking solution, blocking condition, coating solution and coating condition were studied and optimized in the paper. The regression equation of the final inhibition curve is y = - 0.3345x + 1.4955, R²=0.9913. The linear range is 0.1-8.1 ng/ml, and the IC₅₀ is 0.671 ng/ml. The specificity of the assay was evaluated by the cross-reactivity rates of six compounds, of which two structurally related compounds had a relatively higher cross-reactivity rate of 25% and 6%. HES was added into a pork sample at 5 ng/g level and then the sample was extracted. The recovery is between 49.6% and 79.2%, and the variation coefficient is 0.164.     

Survivin和Bcl-2在尖锐湿疣中的表达

目的:测定survivin和Bcl-2在尖锐湿疣(CA)组织中的表达并探讨两者表达的关系。方法:应用免疫组织化学链霉菌抗生物素蛋白过氧化物酶方法(SP法)分别检测60例CA组织及10例正常包皮组织中survivin、Bcl-2基因的表达。在镜下观察切片并计算阳性细胞百分比。结果:CA组织中survivin的表达率为86.67%,显著高于正常包皮的表达率20%(P<0.01)。其中棘层的表达率85.00%显著高于基底层的表达率70.00%和颗粒层的表达率66.67%(P<0.05),基底层与颗粒层的表达率之间无显著性差异(P>0.05)。Bcl-2在CA的表达率为66.67%,正常包皮组织中未见Bcl-2蛋白表达。survivin在CA中的表达与Bcl-2呈正相关(P<0.01)。结论:本实验检测出survivin基因在CA组织中有异常表达,提示survivin蛋白引起的细胞凋亡抑制在CA的发生中起到重要的作用。survivin与Bcl-2在CA的发生发展过程中起到协同作用。     

IDEC-131 (Anti-CD154), Sirolimus and Donor-Specific Transfusion Facilitate Operational Tolerance in Non-Human Primates

CD154-specific antibody therapy prevents allograft rejection in many experimental transplant models. However, initial clinical transplant trials with anti-CD154 have been disappointing suggesting the need for as of yet undetermined adjuvant therapy. In rodents, donor antigen (e.g., a donor blood transfusion), or mTOR inhibition (e.g., sirolimus), enhances anti-CD154's efficacy. We performed renal transplants in major histocompatibility complex-(MHC) mismatched rhesus monkeys and treated recipients with combinations of the CD154-specific antibody IDEC-131, and/or sirolimus, and/or a pre-transplant donor-specific transfusion (DST). Therapy was withdrawn after 3 months. Triple therapy prevented rejection during therapy in all animals and led to operational tolerance in three of five animals including donor-specific skin graft acceptance in the two animals tested. IDEC-131, sirolimus and DST are highly effective in preventing renal allograft rejection in primates. This apparently clinically applicable regimen is promising for human renal transplant trials.